[Relationship of the curative effects of gefitinib on non-small cell lung carcinoma to gender and to epithelial growth factor receptor status].

Abstract

OBJECTIVE:

To investigate the mutation of epithelial growth factor receptor (EGFR) gene in the non-small cell lung carcinoma (LSCLG) patients with different genders and the relationship between the gender of LSCLG patients and the curative effects of gefitinib, an specific tyrosine kinase.

METHODS:

Tumor specimens were obtained from 135 NSCLC patients, 94 males (78.7% smoking) and 41 females (17.1% smoking), of which 20 received gefitinib treatment after the failure of chemotherapy, during operation and stored at -80 degrees C. The genomic DNA of the cancer tissues was extracted by using Trizol reagent. Nest-PCR was used to amplify the exons 18, 19, and 21 of the EGFR gene and the PCR products were purified by agarose electrophoresis and then sequenced.

RESULTS:

EGFR mutation was found in 29 of the 135 NSCLC patients (21.5%), with a mutation rate of 19.1% in the males and a mutation rate of 26.8% in the females (P = 0.344). The mutation types included G719C and G719V in exon 16, delE746 - 750, and delE746 - 751 in exon 19, and L858R and L861Qin exon 21. Among the 20 patients who received gefitinib treatment the disease control rate was 85% (17/20), being 76.9% in the male patients (10/13) and being 100% in the female patients (7/7) (P = 0.521). There were not significant differences in the mean time-to-progression (TTP) between the male and female patients (9 months vs. 14 months, P = 1), and between the patients with the wild type of EGFR gene and those with the mutated type of gene (9 months vs. 14 months, P = 1).

CONCLUSION:

There is no significant relationship between the curative effect of gefitinib on NSCLC and gender and EFGR status.

• Authors: Chong-rui Xu, Jia-ying Lin, Zhen Wang, Qing Zhou, Guo-chun Zhang, Kun Wang, Xue-ning Yang, Gang Chen, Jin-ji Yang, Yu-juan Huang, Ri-qiang Liao, Yi-long Wu
• Journal: Zhonghua yi xue za zhi (Zhonghua Yi Xue Za Zhi) Vol. 86 Issue 37 Pg. 2606-10 (Oct 10 2006) ISSN: 0376-2491 [Print] China
• PMID: 17198584 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Quinazolines
• ErbB Receptors
• Gefitinib

Topics

• Antineoplastic Agents (therapeutic use)
• Base Sequence
• Carcinoma, Non-Small-Cell Lung (drug therapy, genetics, pathology)
• DNA Mutational Analysis
• ErbB Receptors (antagonists & inhibitors, genetics)
• Female
• Gefitinib
• Humans
• Lung Neoplasms (drug therapy, genetics, pathology)
• Male
• Mutation
• Prognosis
• Quinazolines (therapeutic use)
• Sex Factors
• Treatment Outcome